News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
398,273 Results
Type
Article (32069)
Company Profile (58)
Press Release (366146)
Multimedia
Podcasts (41)
Webinars (5)
Section
Business (112828)
Career Advice (1324)
Deals (24051)
Drug Delivery (94)
Drug Development (59733)
Employer Resources (104)
FDA (9962)
Job Trends (9090)
News (211595)
Policy (25539)
Tag
Academia (1843)
Accelerated approval (4)
Adcomms (20)
Allergies (69)
Alliances (42289)
ALS (59)
Alzheimer's disease (1111)
Antibody-drug conjugate (ADC) (100)
Approvals (9956)
Artificial intelligence (165)
Autoimmune disease (17)
Automation (7)
Bankruptcy (237)
Best Places to Work (7694)
BIOSECURE Act (16)
Biosimilars (83)
Biotechnology (42)
Bladder cancer (57)
Brain cancer (28)
Breast cancer (192)
Cancer (1667)
Cardiovascular disease (129)
Career advice (1115)
Career pathing (20)
CAR-T (110)
Cell therapy (305)
Cervical cancer (16)
Clinical research (48285)
Collaboration (692)
Compensation (434)
Complete response letters (19)
COVID-19 (2482)
CRISPR (31)
C-suite (118)
Cystic fibrosis (58)
Data (1577)
Decentralized trials (1)
Denatured (9)
Depression (36)
Diabetes (222)
Diagnostics (3574)
Digital health (10)
Diversity (4)
Diversity, equity & inclusion (33)
Drug discovery (88)
Drug pricing (97)
Drug shortages (28)
Duchenne muscular dystrophy (84)
Earnings (40456)
Editorial (37)
Employer branding (13)
Employer resources (94)
Events (45964)
Executive appointments (328)
FDA (10832)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (482)
Gene editing (74)
Generative AI (13)
Gene therapy (241)
GLP-1 (695)
Government (4105)
Grass and pollen (5)
Guidances (42)
Healthcare (11413)
Huntington's disease (19)
IgA nephropathy (24)
Immunology and inflammation (89)
Indications (24)
Infectious disease (2623)
Inflammatory bowel disease (79)
Inflation Reduction Act (7)
Influenza (52)
Intellectual property (74)
Interviews (231)
IPO (10447)
IRA (40)
Job creations (1750)
Job search strategy (956)
Kidney cancer (7)
Labor market (18)
Layoffs (282)
Leadership (10)
Legal (7060)
Liver cancer (53)
Lung cancer (241)
Lymphoma (114)
Machine learning (7)
Management (32)
Manufacturing (229)
MASH (57)
Medical device (5928)
Medtech (5929)
Mergers & acquisitions (14027)
Metabolic disorders (603)
Multiple sclerosis (54)
NASH (20)
Neurodegenerative disease (73)
Neuropsychiatric disorders (25)
Neuroscience (1511)
NextGen: Class of 2025 (3657)
Non-profit (2772)
Now hiring (5)
Obesity (339)
Opinion (195)
Ovarian cancer (54)
Pain (50)
Pancreatic cancer (68)
Parkinson's disease (116)
Partnered (13)
Patents (167)
Patient recruitment (61)
Peanut (38)
People (24894)
Pharmaceutical (18)
Pharmacy benefit managers (10)
Phase I (14596)
Phase II (20974)
Phase III (17013)
Pipeline (924)
Policy (132)
Postmarket research (1846)
Preclinical (6071)
Press Release (28)
Prostate cancer (83)
Psychedelics (28)
Radiopharmaceuticals (206)
Rare diseases (274)
Real estate (2582)
Recruiting (44)
Regulatory (16175)
Reports (22)
Research institute (1592)
Resumes & cover letters (195)
Rett syndrome (4)
RNA editing (3)
RSV (47)
Schizophrenia (62)
Series A (79)
Series B (43)
Service/supplier (4)
Sickle cell disease (38)
Special edition (5)
Spinal muscular atrophy (137)
Sponsored (19)
Startups (1888)
State (1)
Stomach cancer (11)
Supply chain (55)
Tariffs (30)
The Weekly (31)
Vaccines (716)
Venture capitalists (28)
Weight loss (250)
Women's health (13)
Worklife (10)
Date
Today (92)
Last 7 days (527)
Last 30 days (1632)
Last 365 days (20992)
2025 (6808)
2024 (22354)
2023 (25258)
2022 (33379)
2021 (35888)
2020 (34071)
2019 (27908)
2018 (21234)
2017 (20187)
2016 (18692)
2015 (21494)
2014 (15948)
2013 (12876)
2012 (13623)
2011 (14401)
2010 (13078)
Location
Africa (570)
Alabama (30)
Alaska (3)
Arizona (91)
Arkansas (5)
Asia (25954)
Australia (4681)
California (3650)
Canada (1234)
China (368)
Colorado (155)
Connecticut (161)
Delaware (105)
Europe (62264)
Florida (556)
Georgia (127)
Hawaii (1)
Idaho (28)
Illinois (294)
India (23)
Indiana (191)
Iowa (8)
Japan (123)
Kansas (62)
Kentucky (15)
Louisiana (10)
Maine (28)
Maryland (650)
Massachusetts (2638)
Michigan (102)
Minnesota (141)
Mississippi (1)
Missouri (50)
Montana (20)
Nebraska (10)
Nevada (38)
New Hampshire (21)
New Jersey (1160)
New Mexico (15)
New York (1111)
North Carolina (512)
North Dakota (5)
Northern California (1664)
Ohio (113)
Oklahoma (6)
Oregon (10)
Pennsylvania (804)
Puerto Rico (6)
Rhode Island (13)
South America (797)
South Carolina (11)
South Dakota (1)
Southern California (1366)
Tennessee (52)
Texas (450)
United States (13572)
Utah (83)
Virginia (93)
Washington D.C. (37)
Washington State (306)
West Virginia (2)
Wisconsin (29)
398,273 Results for "numab ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
Numab Therapeutics AG announced that the Company has entered into a definitive agreement whereby Johnson & Johnson acquires Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab to be spun-off to Numab’s shareholders.
May 28, 2024
·
3 min read
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform.
February 14, 2024
·
3 min read
Press Releases
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
January 9, 2025
·
2 min read
Press Releases
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
November 15, 2024
·
3 min read
Drug Development
J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab
Johnson & Johnson’s deal for Numab Therapeutics’ bispecific antibody NM26, slated to enter Phase II studies, comes on the heels of J&J’s $850 million Proteologix bispecific antibody acquisition.
May 28, 2024
·
2 min read
·
Tyler Patchen
Press Releases
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
October 30, 2024
·
3 min read
Drug Development
Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis
Numab Therapeutics AG announced that the first patient has been dosed in the multiple ascending dose study of the Phase 1a/b clinical trial of NM26, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis.
October 19, 2023
·
4 min read
Drug Development
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
Numab Therapeutics AG announced that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis.
May 15, 2023
·
5 min read
Press Releases
Bacteria in Our Aging Guts Can Elevate Risk of Leukemia
April 24, 2025
·
7 min read
Press Releases
Additional Member for the Board of Directors of Bachem Holding AG
April 3, 2025
·
3 min read
1 of 39,828
Next
